weight-loss drugs

Factory activity slowed across much of Asia in May as uncertainty over U.S. tariffs continued to cause steep declines in new orders, purchasing ma...

The National Pension Service (NPS), South Korea’s state-run pension fund and the country’s largest institutional investor, announced on ...

Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufac...

Rznomics Inc., a South Korean RNA therapeutics developer, has signed an agreement worth more than $1.3 billion with US pharmaceutical giant Eli Lill...

South Korea’s second-largest conglomerate SK Group is seeking to divest SK Signet Inc., four years after acquiring the EV charger manufacturin...

United Arab Emirates’ sovereign wealth fund Mubadala Investment Co. and Goldman Sachs are set to invest a combined $700 million in Kakao Mobil...

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

Kakao Entertainment Corp. has been divesting unprofitable music labels and digital content platforms, which it has gobbled up over the past few year...

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...

South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...

Samsung Electronics Co. Chairman Lee Jae-yong has warned the company's executives that the South Korean tech giant has lost its characteristic "rele...

Chinese stocks are attracting South Korean investors looking beyond Wall Street amid the downturn in US Big Tech stocks.South Korea’s equity f...

South Korea’s National Pension Service (NPS), the nation’s biggest institutional investor, could lose more than 1 trillion won ($692 mil...

South Korea’s foreign exchange reserves diminished to the lowest level in nearly five years last month, largely due to the expanded forex swap...

Chong Kun Dang Pharmaceutical Corp. is discussing building a research center and a plant in Siheung, about 30 kilometers southwest of Seoul, with th...

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

South Korean institutional investors, including banks, insurers and securities companies, have yet to fully benefit from recent declines in bond yie...

SK Hynix Inc., the top supplier of high-bandwidth memory (HBM) chips to Nvidia Corp., on Thursday reported its highest-ever quarterly profit of 8.08...

SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...

SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...

South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture ...

LG Energy Solution Ltd. reported its first quarterly loss in more than three years on Thursday, adding to concerns that the world’s third-larg...

Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...

South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and...

South Korea’s Finance Minister Choi Sang-mok said on Friday that President Yoon Suk Yeol’s failed martial law attempt will have a very l...

South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...

South Korea’s Hanmi Pharmaceutical Co. announced on Thursday the launch of its anti-obesity drug candidate efpeglenatide has been rescheduled ...